Note: This document contains side effect information about galcanezumab. Some dosage forms listed on this page may not apply to the brand name Emgality.
Applies to galcanezumab: subcutaneous solution.
Serious side effects of Emgality
Along with its needed effects, galcanezumab (the active ingredient contained in Emgality) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking galcanezumab:
Incidence not known
- Difficulty breathing
- fast heartbeat
- fever
- hives, itching, skin rash
- hoarseness
- irritation
- joint pain, stiffness, or swelling
- redness of the skin
- swelling of the eyelids, face, lips, hands, or feet
- tightness in the chest
- trouble with swallowing
Other side effects of Emgality
Some side effects of galcanezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For Healthcare Professionals
Applies to galcanezumab: subcutaneous solution.
General
The most commonly reported adverse reaction has been injection site reactions.[Ref]
Hypersensitivity
Frequency not reported: Hypersensitivity reactions (including dyspnea, urticaria, and rash)
Postmarketing reports: Anaphylaxis, angioedema[Ref]
Immunologic
Very common (10% or more): Anti-Drug-Antibodies (up to 12.5%)[Ref]
Local
Very common (10% or more): Injection site reactions (18%)[Ref]
Injection site reaction included event terms such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus.[Ref]
Other
Common (1% to 10%): Vertigo
Dermatologic
Common (1% to 10%): Pruritus
Uncommon (0.1% to 1%): Urticaria
Postmarketing reports: Rash
Gastrointestinal
Common (1% to 10%): Constipation
